Holen Sie sich die Stockscreener-App
1.20
13.21%
0.14
Schlusskurs vom Vortag:
$1.06
Offen:
$1.05
24-Stunden-Volumen:
164.54K
Relative Volume:
0.39
Marktkapitalisierung:
$63.36M
Einnahmen:
$2.91M
Nettoeinkommen (Verlust:
$-220.40M
KGV:
-0.3297
EPS:
-3.64
Netto-Cashflow:
$-176.15M
1W Leistung:
+6.19%
1M Leistung:
-13.67%
6M Leistung:
-92.00%
1J Leistung:
-85.65%
1-Tages-Spanne:
$1.02
$1.20
1-Wochen-Bereich:
$0.92
$1.20
52-Wochen-Spanne:
$0.92
$22.50
Igm Biosciences Inc Stock (IGMS) Company Profile
Firmenname
Igm Biosciences Inc
Sektor
Branche
Telefon
650-965-7873
Adresse
325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW
Vergleichen Sie IGMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IGMS
Igm Biosciences Inc
|
1.20 | 63.36M | 2.91M | -220.40M | -176.15M | -3.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.22 | 122.24B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.18 | 59.73B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.94 | 35.43B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
237.77 | 30.77B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
96.52 | 23.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
Igm Biosciences Inc Stock (IGMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-01-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-01-10 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2025-01-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-01-10 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-10-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-10-01 | Herabstufung | Truist | Buy → Hold |
| 2024-02-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-11-09 | Fortgesetzt | Jefferies | Buy |
| 2022-10-17 | Eingeleitet | JP Morgan | Neutral |
| 2022-08-29 | Eingeleitet | BofA Securities | Buy |
| 2021-12-13 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-05 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-08-26 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-01-29 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-01-19 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-22 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-07-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-07-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-28 | Eingeleitet | SunTrust | Buy |
| 2020-04-22 | Eingeleitet | Wedbush | Outperform |
| 2019-10-14 | Eingeleitet | Guggenheim | Buy |
| 2019-10-14 | Eingeleitet | Jefferies | Buy |
| 2019-10-14 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-10-14 | Eingeleitet | Stifel | Buy |
Alle ansehen
Igm Biosciences Inc Aktie (IGMS) Neueste Nachrichten
IGMS stock touches 52-week low at $1 amid sharp annual decline By Investing.com - Investing.com South Africa
IGMS stock touches 52-week low at $1 amid sharp annual decline - Investing.com India
IGM Bio stock slips as Bank of America downgrades (IGMS:NASDAQ) - Seeking Alpha
Short Interest in IGM Biosciences, Inc. (NASDAQ:IGMS) Decreases By 19.3% - MarketBeat
IGMS STOCK ALERT: Levi & Korsinsky Notifies IGM Biosciences, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
IGMS stock plunges to 52-week low at $1.14 amid market challenges - Investing.com Australia
IGMS stock plunges to 52-week low at $1.14 amid market challenges By Investing.com - Investing.com South Africa
Charles Schwab Investment Management Inc. Buys 9,441 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
IGM Biosciences (NASDAQ:IGMS) Shares Up 5.9%What's Next? - MarketBeat
IGM Biosciences stock plunges to 52-week low of $1.59 - MSN
IGM Biosciences, Inc. (NASDAQ:IGMS) Given Average Rating of "Reduce" by Brokerages - MarketBeat
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives $5.50 Consensus PT from Brokerages - Defense World
IGM Biosciences (NASDAQ:IGMS) Shares Up 5.9% – Here’s Why - Defense World
Sanofi Advances Immunology Ambitions With Dren Deal - insights.citeline.com
IGM Biosciences CEO Mary Beth Harler sells $9,014 in stock By Investing.com - Investing.com Australia
IGM Biosciences CFO Tahir Misbah sells shares worth $9,014 By Investing.com - Investing.com South Africa
IGM Biosciences chief business officer sells $5,549 in stock By Investing.com - Investing.com South Africa
IGM Biosciences CEO Mary Beth Harler sells $9,014 in stock - Investing.com India
IGM Biosciences chief business officer sells $5,549 in stock - Investing.com India
IGM Biosciences CFO Tahir Misbah sells shares worth $9,014 - Investing.com India
Igm biosciences officer sells shares worth $2,092 - Investing.com India
Igm biosciences officer sells shares worth $2,092 By Investing.com - Investing.com Australia
IGM Biosciences stock plunges to 52-week low at $1.17 By Investing.com - Investing.com Australia
IGM Biosciences stock plunges to 52-week low at $1.17 - Investing.com India
IGM Biosciences Faces Uncertainty Amid Cash Preservation and Restructuring Efforts - TipRanks
IGM Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Contrasting IGM Biosciences (NASDAQ:IGMS) and Gyre Therapeutics (NASDAQ:GYRE) - Defense World
IGM Biosciences stock plunges to 52-week low of $1.25 By Investing.com - Investing.com Australia
IGM Biosciences stock plunges to 52-week low of $1.25 - Investing.com India
IGM Biosciences Inc expected to post a loss of 74 cents a shareEarnings Preview - TradingView
IGM Biosciences (IGMS) Projected to Post Quarterly Earnings on Thursday - MarketBeat
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - MSN
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Rating of “Reduce” from Brokerages - Defense World
Can Senti Bio's New Executives Accelerate Its Novel Cell Therapy Programs? - Stock Titan
IGM to slash 73% of workforce, halt two drug programs - MSN
Promising US Penny Stocks To Watch In February 2025 - simplywall.st
Fierce Biotech Layoff Tracker 2025: Encoded trims 29% of team; Inventiva halves staff - Fierce Biotech
Finanzdaten der Igm Biosciences Inc-Aktie (IGMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Igm Biosciences Inc-Aktie (IGMS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Tahir Misbah | CHIEF FINANCIAL OFFICER |
Mar 14 '25 |
Sale |
1.23 |
7,329 |
9,015 |
180,324 |
| Harler Mary Beth | Chief Executive Officer |
Mar 14 '25 |
Sale |
1.23 |
7,329 |
9,015 |
339,703 |
| Decker Lisa Lynn | CHIEF BUSINESS OFFICER |
Mar 14 '25 |
Sale |
1.23 |
4,512 |
5,550 |
73,529 |
4.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):